AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 78_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 11_CD Fixed_VBN asset_NN investments_NNS Joint_NNP Other_JJ ventures_NNS investments_NNS Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN At_IN beginning_NN of_IN year_NN 134_CD 46_CD 180_CD Additions_NNS 120_CD 120_CD Disposals_NNS and_CC other_JJ movements_NNS ,_, including_VBG exchange_NN 54_CD 54_CD At_IN end_NN of_IN year_NN 134 220 354_CD Share_NN of_IN post-acquisition_JJ reserves_NNS At_IN beginning_NN and_CC end_NN of_IN year_NN 134_CD 134_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2003 220 220_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002_CD 46_CD 46_CD The_DT fair_JJ values_NNS of_IN other_JJ investments_NNS are_VBP not_RB materially_RB different_JJ from_IN their_PRP$ carrying_VBG values_NNS ._.
At_IN 31_CD December_NNP 2003_CD ,_, the_DT Groups_NNS share_VBP ownership_NN trusts_NNS held_VBD 1,668,299_CD Ordinary_NNP Shares_NNP ._.
Share_NN of_IN joint_JJ venture_NN assets_NNS and_CC liabilities_NNS 2003_CD 2002_CD $_$ m_CD $_$ m_CD Gross_NNP assets_NNS 174_CD 107_CD Gross_NNP liabilities_NNS 174_CD 107_CD 12_CD Stocks_NNS 2003_CD 2002_CD $_$ m_CD $_$ m_CD Raw_NNP materials_NNS and_CC consumables_NNS 715_CD 756_CD Stocks_NNS in_IN process_NN 1,206_CD 1,071_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 1,101_CD 766_CD 3,022_CD 2,593_CD The_DT 2002_CD stock_NN analysis_NN has_VBZ been_VBN recategorised_VBN ._.
